What is Dynacure?
Founded in 2016, Dynacure operates at the intersection of advanced medical research and patient-centric therapeutic development. The company is dedicated to transforming the lives of patients suffering from rare diseases, particularly those who currently face limited or no viable treatment options. By leveraging a robust scientific platform, Dynacure focuses on the discovery and commercialization of innovative therapies that address high unmet medical needs. Its market position is bolstered by a disciplined approach to clinical trials and a strategic focus on high-impact, specialized medicine, positioning the firm as a key player in the European and global biotech ecosystem.
How much funding has Dynacure raised?
Dynacure has raised a total of $110M across 2 funding rounds:
Series A
$55M
Series C
$55M
Series A (2018): $55M with participation from Andera Partners, Kurma Partners, Bpifrance, Pontifax, and IdInvest Partners
Series C (2020): $55M led by Bpifrance, Andera Partners, Tekla Capital Management, and Perceptive Advisors
Key Investors in Dynacure
Bpifrance
Founded in 2012, Bpifrance is a French public investment bank that supports companies at every stage of development through credit, guarantees, and equity, with a strong focus on innovation and international expansion.
Perceptive Advisors
A New York-based investment firm managing approximately $7 billion in assets, specializing in funding innovative healthcare and life sciences technologies.
Kurma Partners
A prominent European venture capital firm that focuses on healthcare and biotechnology, transforming disruptive scientific discoveries into advanced medical solutions for severe diseases.
What's next for Dynacure?
With the infusion of recent capital, Dynacure is well-positioned to scale its clinical operations and advance its lead candidates through critical regulatory milestones. The strategic focus will likely shift toward expanding its internal research capabilities and strengthening its intellectual property portfolio. As the company moves deeper into its clinical-stage lifecycle, the emphasis will remain on executing rigorous trial protocols and exploring potential partnerships that could enhance its commercial reach. Investors will be closely monitoring the firm's ability to translate its scientific breakthroughs into tangible patient outcomes, which remains the primary driver of long-term value creation in the rare disease sector.
See full Dynacure company page
